Anti-Human IL-6 (Sarilumab) - Fc Mutedâ„¢
Anti-Human IL-6 (Sarilumab) - Fc Mutedâ„¢ (LT1705-GRP)
Products
Description
IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects.
Specifications
| Manufacturer | Leinco Technologies Inc |
|---|---|
| Manufacturer Cat# | LT1705 |
| Concentration | ≥ 5.0 mg/ml |
| Formulation | This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. |
| Clone | Hu137 |
| Target | IL-6 |
| Applications | B, ELISA, FA, FC, IHC, N, WB |
| Antigen | IL-6R is ubiquitously expressed. |
| Storage | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Protein | IL-6 |